Journal article
Putative biological predictors of treatment response in bipolar disorders
Personalized Medicine in Psychiatry, Vol.1-2, pp.39-58
03/2017
DOI: 10.1016/j.pmip.2016.11.003
Abstract
Bipolar disorder (BD) is a debilitating illness that affects millions of Americans each year and is the 6th leading cause of disability in the world. Although standard treatments are available for management of BD, approximately half of all BD patients are either non-adherent or poorly adherent with prescribed medication regimens, resulting in decreased quality of life and increases in relapse rates, costs of care, and suicide attempts. Noncompliance in BD is often related to medication side effects and perceived lack of efficacy, which underscores the importance of trying to improve the “trial and error” process of finding optimal individualized treatments. There is a great need for more specific and sensitive biomarkers for the monitoring of BD treatment response, as well as predictive biomarkers to identify who is most likely to respond to these treatments and to avoid adverse effects. Here, we provide a comprehensive review on the utility of peripheral biomarkers for treatment response in bipolar disorder. We focus on the five most promising key areas for biological predictors of treatment response: 1) cell growth, cell survival, and synaptic plasticity (neurotrophins and growth factors), 2) energy metabolism (oxidative stress and mitochondrial function), 3) inflammation (pro- and anti-inflammatory cytokines), 4) stress response (neuroendocrine response), and 5) peripheral gene expression.
Details
- Title: Subtitle
- Putative biological predictors of treatment response in bipolar disorders
- Creators
- Suzanne D Gonzalez - Department of Biomedical Sciences, Texas Tech University Health Sciences Center, El Paso, TX, USAAislinn J Williams - Department of Psychiatry, University of Michigan, Ann Arbor, MI, USACaren J Blacker - Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USAJennifer L Vande Voort - Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USAKathryn M Schak - Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USACharles B Nemeroff - Department of Psychiatry and Behavioral Sciences, University of Miami, Miami, FL, USAAlik S Widge - The American Psychiatric Association Task Force on Biomarkers and Novel Treatments, USAMauricio Tohen - The American Psychiatric Association Task Force on Biomarkers and Novel Treatments, USA
- Resource Type
- Journal article
- Publication Details
- Personalized Medicine in Psychiatry, Vol.1-2, pp.39-58
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.pmip.2016.11.003
- ISSN
- 2468-1717
- Language
- English
- Date published
- 03/2017
- Academic Unit
- Psychiatry; Iowa Neuroscience Institute
- Record Identifier
- 9984066378402771
Metrics
26 Record Views